Application of CE-MS to a metabonomics study of human urine from cigarette smokers and non-smokers

Bioanalysis

Volumn 6, Issue 20, 2014, Pages 2733-2749

  Garcia Perez, Isabel ^a   Lindon, John C ^a   Minet, Emmanuel ^b  

^a Bioincubator   (United Kingdom)

^b BRITISH AMERICAN TOBACCO   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYCOTININE; BIOLOGICAL MARKER; COTININE; COTININE N BETA DEXTRO GLUCURONIDE; GLYCINE; GUANIDINOACETIC ACID; NICOTINE; NICOTINE 1 OXIDE; NICOTINE DERIVATIVE; NICOTINE N BETA DEXTRO GLUCURONIDE; TAR; TRANS 3' HYDROXYCOTININE O BETA DEXTRO GLUCURONIDE; UNCLASSIFIED DRUG;

ARTICLE; BIOMICS; CAPILLARY ELECTROPHORESIS; CHEMOMETRIC ANALYSIS; CODING; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; ENDOGENOUS METABOLISM; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; METABOLISM; METABONOMICS; NAMED GROUPS OF PERSONS; NON SMOKER; OXIDATIVE STRESS; PHENOTYPE; REFERENCE VALUE; SMOKING; TIME OF FLIGHT MASS SPECTROMETRY; URINALYSIS; VALIDATION PROCESS; MASS FRAGMENTOGRAPHY; METABOLOMICS; PROCEDURES; URINE;

GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; METABOLOMICS; NICOTINE; SMOKING;

EID: 84913593498     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.136     Document Type: Article

References (81)

1. Perfetti TA, Rodgman A. The complexity of tobacco and tobacco smoke. Contributions to tobacco research. Beitr. Tabakforsch 24(5), 215-232 (2011).
2. Food and Drug Administration (FDA). Harmful and potentially harmful constituents in tobacco products and tobacco smoke; established list. www.fda.gov/TobaccoProducts/ GuidanceComplianceRegulatoryInformation/ucm297786. htm.
3. Hatsukami DK, Slade J, Benowitz NL et al. Reducing tobacco harm: research challenges and issues. Nicotine Tob. Res. 4(2), S89-S101 (2002).
4. Zeller M, Hatsukami D. Strategic dialogue on tobacco harm reduction G: the strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tob. Control 18(4), 324-332 (2009).
5. Debethizy JD, Borgerding MF, Doolittle DJ et al. Chemical and biological studies of a cigarette that heats rather than burns tobacco. J. Clin. Pharmacol. 30(8), 755-763 (1990).
6. Leischow SJ, Zeller M, Backinger CL. Research priorities and infrastructure needs of the Family Smoking Prevention and Tobacco Control Act: science to inform FDA policy. Nicotine Tob. Res. 14(1), 1-6 (2012).
7. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
8. Gyorffy E, Anna L, Kovacs K et al. Correlation between biomarkers of human exposure to genotoxins with focus on carcinogen-DNA adducts. Mutagenesis 23(1), 1-18 (2008).
9. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat. Rev. Cancer 3(10), 733-744 (2003).
10. Gregg EO, Minet E, Mcewan M. Urinary biomarkers of smokers' exposure to tobacco smoke constituents in tobacco products assessment: a fit for purpose approach. Biomarkers 18(6), 467-486 (2013).
11. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29(11), 1181-1189 (1999).
12. Bjerrum JT, Nielsen OH, Hao F et al. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J. Proteome Res. 9(2), 954-962 (2010).
13. Chan EC, Koh PK, Mal M et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 8(1), 352-361 (2009).
14. Holmes E, Bonner FW, Sweatman BC et al. Nuclear magnetic resonance spectroscopy and pattern recognition analysis of the biochemical processes associated with the progression of and recovery from nephrotoxic lesions in the rat induced by mercury(II) chloride and 2-bromoethanamine. Mol. Pharmacol. 42(5), 922-930 (1992).
15. Ikeda A, Nishiumi S, Shinohara M et al. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed. Chrom. 26(5), 548-558 (2012).
16. Lindon JC, Holmes E, Bollard ME et al. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 9(1), 1-31 (2004).
17. Moolenaar SH, Engelke UF, Wevers RA. Proton nuclear magnetic resonance spectroscopy of body fluids in the field of inborn errors of metabolism. Ann. Clin. Biochem. 40(Pt 1), 16-24 (2003).
18. Sitter B, Sonnewald U, Spraul M et al. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed. 15(5), 327-337 (2002).
19. Clayton TA, Baker D, Lindon JC et al. Pharmacometabonomic identification of a significant hostmicrobiome metabolic interaction affecting human drug metabolism. Proc. Natl Acad. Sci. 106(34), 14728-14733 (2009).
20. Clayton TA, Lindon JC, Cloarec O et al. Pharmacometabonomic phenotyping and personalized drug treatment. Nature 440(7087), 1073-1077 (2006).
21. Athersuch TJ. The role of metabolomics in characterizing the human exposome. Bioanalysis 4(18), 2207-2212 (2012).
22. Ellis JK, Athersuch TJ, Thomas LD et al. Metabolic profiling detects early effects of environmental and lifestyle exposure to cadmium in a human population. BMC Med. 10, 61 (2012).
23. Wishart DS. Advances in metabolite identification. Bioanalysis 3(15), 1769-1782 (2011).
24. Beckonert O, Keun HC, Ebbels TM et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2(11), 2692-2703 (2007).
25. Want EJ, Wilson ID, Gika H et al. Global metabolic profiling procedures for urine using UPLC-MS. Nat. Protoc. 5(6), 1005-1018 (2010).
26. Garcia-Perez I, Couto Alves A, Angulo S et al. Bidirectional correlation of NMR and capillary electrophoresis fingerprints: a new approach to investigating Schistosoma mansoni infection in a mouse model. Anal. Chem. 82(1), 203-210 (2009).
27. Lindon JC, Nicholson JK. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu. Rev. Anal. Chem. 1, 45-69 (2008).
28. Lenz EM, Wilson ID. Analytical strategies in metabonomics. J. Proteome Res. 6(2), 443-458 (2007).
29. Scalbert A, Brennan L, Fiehn O et al. Mass-spectrometrybased metabolomics: limitations and recommendations for future progress with particular focus on nutrition research. Metabolomics 5(4), 435-458 (2009).
30. Zhang A, Sun H, Wang P et al. Modern analytical techniques in metabolomics analysis. Analyst 137(2), 293-300 (2012).
31. Song H, Wang L, Liu HL et al. Tissue metabolomic fingerprinting reveals metabolic disorders associated with human gastric cancer morbidity. Oncol. Rep. 26(2), 431-438 (2011).
32. Vallejo M, Garcia A, Tunon J et al. Plasma fingerprinting with GC-MS in acute coronary syndrome. Anal. Bioanal. Chem. 394(6), 1517-1524 (2009).
33. Mueller DC, Piller M, Niessner R et al. Untargeted metabolomic profiling in saliva of smokers and non-smokers by a validated GC-TOF-MS method. J. Proteome Res. 13(3), 1602-1613 (2014).
34. Garcia-Perez I, Vallejo M, Garcia A et al. Metabolic fingerprinting with capillary electrophoresis. J. Chromatogr. A 1204(2), 130-139 (2008).
35. Ramautar R, Somsen GW, De Jong GJ. CE-MS in metabolomics. Electrophoresis 30(1), 276-291 (2009).
36. Monton MR, Soga T. Metabolome analysis by capillary electrophoresis-mass spectrometry. J. Chromatogr. A 1168(1-2), 237-246 (2007).
37. Ramautar R, Mayboroda OA, Somsen GW et al. CE-MS for metabolomics: developments and applications in the period 2008-2010. Electrophoresis 32(1), 52-65 (2011).
38. Ramautar R, Somsen GW, De Jong GJ. CE-MS for metabolomics: developments and applications in the period 2010-2012. Electrophoresis 34(1), 86-98 (2013).
39. Saric J, Want EJ, Duthaler U et al. Systematic evaluation of extraction methods for multiplatform-based metabotyping: application to the Fasciola hepatica metabolome. Anal. Chem. 84(16), 6963-6972 (2012).
40. Simo C, Barbas C, Cifuentes A. Capillary electrophoresismass spectrometry in food analysis. Electrophoresis 26(7-8), 1306-1318 (2005).
41. Muller DC, Degen C, Scherer G et al. Metabolomics using GC-TOF-MS followed by subsequent GC-FID and HILIC-MS/MS analysis revealed significantly altered fatty acid and phospholipid species profiles in plasma of smokers. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1(966), 117-126 (2014).
42. Xu T, Holzapfel C, Dong X et al. Effects of smoking and smoking cessation on human serum metabolite profile: results from the KORA cohort study. BMC Med. 11, 60 (2013).
43. Hsu PC, Zhou B, Zhao Y et al. Feasibility of identifying the tobacco-related global metabolome in blood by UPLCQTOF- MS. J. Proteome Res. 12(2), 679-691 (2013).
44. Ryan D, Robards K, Prenzler PD et al. Recent and potential developments in the analysis of urine: a review. Anal. Chim. Acta 684(1-2), 8-20 (2011).
45. Shepperd CJ, Eldridge AC, Mariner DC et al. A study to estimate and correlate cigarette smoke exposure in smokers in Germany as determined by filter analysis and biomarkers of exposure. Regul. Toxicol. Pharmacol. 55(1), 97-109 (2009).
46. Maher AD, Zirah SF, Holmes E et al. Experimental and analytical variation in human urine in 1H NMR spectroscopy-based metabolic phenotyping studies. Anal. Chem. 79(14), 5204-5211 (2007).
47. The Handbook of Metabonomics and Metabolomics. Lindon JC, Nicholson JK, Holmes E (Eds). Elsevier, The Netherlands (2000).
48. Riboli E, Haley NJ, De Waard F et al. Validity of urinary biomarkers of exposure to tobacco smoke following prolonged storage. Int. J. Epidemiol. 24(2), 354-358 (1995).
49. Xia Y, Bernert JT. Stability of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in urine samples stored at various temperatures. J. Anal. Toxicol. 34(7), 411-415 (2010).
50. Gika HG, Macpherson E, Theodoridis GA et al. Evaluation of the repeatability of ultra-performance liquid chromatography-TOF-MS for global metabolic profiling of human urine samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 871(2), 299-305 (2008).
51. Halimi JM, Giraudeau B, Vol S et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int. 58(3), 1285-1292 (2000).
52. Smith CA, O'maille G, Want EJ et al. METLIN -A metabolite mass spectral database. Ther. Drug Monit. 27(6), 747-751 (2005).
53. Wishart DS, Knox C, Guo AC et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 37, D603-D610 (2009).
54. Baidoo EE, Clench MR, Smith RF et al. Determination of nicotine and its metabolites in urine by solid-phase extraction and sample stacking capillary electrophoresis-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 796(2), 303-313 (2003).
55. Fisher RA. In: Statistical Methods for Research Workers. Oliver and Boyd, Edinburgh
56. Spitale RC, Cheng MY, Chun KA et al. Differential effects of dietary supplements on metabolomic profile of smokers versus non-smokers. Genome Med. 4(2), 14 (2012).
57. Kozlowski LT, Pillitteri JL, Sweeney CT. Misuse of "light" cigarettes by means of vent blocking. J. Subst. Abuse 6(3), 333-336 (1994).
58. Djordjevic MV, Stellman SD, Zang E. Doses of nicotine and lung carcinogens delivered to cigarette smokers. J. Natl. Cancer Inst. 92(2), 106-111 (2000).
59. Hecht SS, Murphy SE, Carmella SG et al. Similar uptake of lung carcinogens by smokers of regular, light, and ultralight cigarettes. Cancer Epidemiol. Biomarkers 14(3), 693-698 (2005).
60. Stieber J, Hartel U, Heller WD et al. Smoking habits and attitude to smoking in the study population of the MONICA Project Augsburg. Soz. Praventivmed. 33(1), 22-26 (1988).
61. Lu SC. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J. 13(10), 1169-1183 (1999).
62. Wendel A, Hahn R, Guder WG. On the role of gammaglutamyltransferase in renal tubular amino acid reabsorption. Curr. Probl. Clin. Biochem. 6, 426-436 (1976).
63. Vulimiri SV, Misra M, Hamm JT et al. Effects of mainstream cigarette smoke on the global metabolome of human lung epithelial cells. Chem. Res. Toxicol. 22(3), 492-503 (2009).
64. Tanriverdi H, Evrengul H, Kuru O et al. Cigarette smoking induced oxidative stress may impair endothelial function and coronary blood flow in angiographically normal coronary arteries. Circ. J. 70(5), 593-599 (2006).
65. Rahman Q, Abidi P, Afaq F et al. Glutathione redox system in oxidative lung injury. Crit. Rev. Toxicol. 29(6), 543-568 (1999).
66. Vibhuti A, Arif E, Deepak D et al. Correlation of oxidative status with BMI and lung function in COPD. Clin. Biochem. 40(13-14), 958-963 (2007).
67. Toth KM, Berger EM, Beehler CJ et al. Erythrocytes from cigarette smokers contain more glutathione and catalase and protect endothelial cells from hydrogen peroxide better than do erythrocytes from nonsmokers. Am. Rev. Respir. 134(2), 281-284 (1986).
68. Rahman I, Macnee W. Lung glutathione and oxidative stress: implications in cigarette smoke-induced airway disease. Am. J. Physiol. 277(6 Pt 1), L1067-1088 (1999).
69. Gould NS, Min E, Gauthier S et al. Lung glutathione adaptive responses to cigarette smoke exposure. Respir. Res. 12, 133 (2011).
70. Rahman I, Van Schadewijk AA, Hiemstra PS et al. Localization of gamma-glutamylcysteine synthetase messenger RNA expression in lungs of smokers and patients with chronic obstructive pulmonary disease. Free Radic. Biol. Med. 28(6), 920-925 (2000).
71. Larsson A, Mattsson B. On the mechanism of 5-oxoproline overproduction in 5-oxoprolinuria. Clin. Chim. Acta 67(3), 245-253 (1976).
72. Forrester TE, Badaloo V, Bennett FI et al. Excessive excretion of 5-oxoproline and decreased levels of blood glutathione in type II diabetes mellitus. Eur. J. Clin. Nutr. 44(11), 847-850 (1990).
73. Van Der Werf P, Griffith OW, Meister A. 5-Oxo-l-prolinase (l-pyroglutamate hydrolase). Purification and catalytic properties. J. Biol. Chem. 250(17), 6686-6692 (1975).
74. Soga T, Baran R, Suematsu M et al. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J. Biol. Chem. 281(24), 16768-16776 (2006).
75. Luppi F, Aarbiou J, Van Wetering S et al. Effects of cigarette smoke condensate on proliferation and wound closure of bronchial epithelial cells in vitro: role of glutathione. Resp. Res. 6, 140 (2005).
76. Vibhuti A, Arif E, Deepak D et al. Correlation of oxidative status with BMI and lung function in COPD. Clin. Biochem. 40(13-14), 958-963 (2007).
77. Jenks BH, Mckee RW, Swendseid ME et al. Methylated niacin derivatives in plasma and urine after an oral dose of nicotinamide given to subjects fed a low-methionine diet. Am. J. Clin. Nutr. 46(3), 496-502 (1987).
78. Surjana D, Halliday GM, Damian DL. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. J. Nucleic Acids 2010, 157591 (2010).
79. Rocha CM, Carrola J, Barros AS et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J. Proteome Res. 10(9), 4314-4324 (2011).
80. Srivastava S, Roy R, Singh S et al. Taurine -a possible fingerprint biomarker in non-muscle invasive bladder cancer: A pilot study by 1H NMR spectroscopy. Cancer Biomark 6(1), 11-20 (2010).
81. Travis WD et al. Cancer IaFRO, Pathology IaO. In: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, France (2004).